Danaher Co. (DHR) Expected to Announce Quarterly Sales of $4.92 Billion

Equities research analysts expect Danaher Co. (NYSE:DHR) to announce sales of $4.92 billion for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Danaher’s earnings. The highest sales estimate is $4.98 billion and the lowest is $4.77 billion. Danaher posted sales of $4.51 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 9.1%. The business is expected to report its next quarterly earnings report before the market opens on Thursday, July 19th.

On average, analysts expect that Danaher will report full-year sales of $19.91 billion for the current fiscal year, with estimates ranging from $19.69 billion to $20.03 billion. For the next fiscal year, analysts anticipate that the company will post sales of $20.84 billion per share, with estimates ranging from $20.68 billion to $21.04 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Danaher.

Danaher (NYSE:DHR) last released its earnings results on Thursday, April 19th. The conglomerate reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.05. Danaher had a return on equity of 11.39% and a net margin of 13.56%. The business had revenue of $4.70 billion during the quarter, compared to the consensus estimate of $4.54 billion. During the same period last year, the company earned $0.85 earnings per share. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year.

DHR has been the subject of several research analyst reports. Zacks Investment Research downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Monday, March 26th. Credit Suisse Group lifted their price objective on Danaher from $106.00 to $108.00 and gave the company an “outperform” rating in a report on Tuesday, March 13th. ValuEngine upgraded Danaher from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Stifel Nicolaus restated a “buy” rating and issued a $114.00 price objective (up from $108.00) on shares of Danaher in a report on Thursday, April 19th. Finally, Morgan Stanley lifted their price objective on Danaher from $110.00 to $112.00 and gave the company an “overweight” rating in a report on Tuesday, April 10th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $105.69.

In other Danaher news, CFO Daniel L. Comas sold 25,206 shares of Danaher stock in a transaction dated Friday, April 20th. The stock was sold at an average price of $101.39, for a total value of $2,555,636.34. Following the transaction, the chief financial officer now owns 148,769 shares in the company, valued at $15,083,688.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daniel L. Comas sold 78,379 shares of Danaher stock in a transaction dated Monday, April 23rd. The shares were sold at an average price of $101.67, for a total value of $7,968,792.93. Following the completion of the transaction, the chief financial officer now owns 148,769 shares in the company, valued at approximately $15,125,344.23. The disclosure for this sale can be found here. Insiders sold 241,940 shares of company stock worth $24,527,925 in the last quarter. 11.90% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Gulf International Bank UK Ltd grew its stake in shares of Danaher by 0.3% during the first quarter. Gulf International Bank UK Ltd now owns 197,012 shares of the conglomerate’s stock worth $19,289,000 after acquiring an additional 520 shares during the last quarter. Ramsay Stattman Vela & Price Inc. grew its stake in shares of Danaher by 0.7% during the first quarter. Ramsay Stattman Vela & Price Inc. now owns 84,028 shares of the conglomerate’s stock worth $8,227,000 after acquiring an additional 550 shares during the last quarter. Jacobi Capital Management LLC grew its stake in shares of Danaher by 15.5% during the first quarter. Jacobi Capital Management LLC now owns 4,448 shares of the conglomerate’s stock worth $427,000 after acquiring an additional 597 shares during the last quarter. NuWave Investment Management LLC grew its stake in shares of Danaher by 6.6% during the first quarter. NuWave Investment Management LLC now owns 9,904 shares of the conglomerate’s stock worth $964,000 after acquiring an additional 612 shares during the last quarter. Finally, Avalon Advisors LLC grew its stake in shares of Danaher by 0.6% during the first quarter. Avalon Advisors LLC now owns 109,233 shares of the conglomerate’s stock worth $10,695,000 after acquiring an additional 621 shares during the last quarter. Institutional investors own 76.61% of the company’s stock.

NYSE:DHR opened at $99.50 on Tuesday. Danaher has a twelve month low of $78.97 and a twelve month high of $104.82. The firm has a market cap of $69.39 billion, a PE ratio of 24.69, a price-to-earnings-growth ratio of 1.86 and a beta of 1.05. The company has a quick ratio of 1.15, a current ratio of 1.59 and a debt-to-equity ratio of 0.38.

The business also recently announced a quarterly dividend, which will be paid on Friday, July 27th. Shareholders of record on Friday, June 29th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Thursday, June 28th. This represents a $0.64 annualized dividend and a yield of 0.64%. Danaher’s dividend payout ratio (DPR) is presently 15.88%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.

Get a free copy of the Zacks research report on Danaher (DHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply